AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method for treating amyotrophic lateral sclerosis or symptoms caused by amyotrophic lateral sclerosis and/or suppressing the progression thereof, which comprises administering to a patient in need thereof as an active ingredient 3-methyl-1-phenyl-2-pyrazoline-5-one, or a physiologically acceptable salt thereof, or a hydrate thereof,

under the condition that a combination of a drug administration period of 1 day to about 14 days and a drug holiday period of 1 day to about 14 days is repeated ~~a drug holiday period of 1 day or more is provided once, twice or more~~ during the period for treating the disease or suppressing the progression of the disease.

2. (Cancelled)

3. (Previously Presented) The method of claim 1, wherein the drug holiday period is provided after a drug administration period of about 7 to 14 days.

4. (Previously Presented) The method of claim 1, wherein a second or subsequent drug administration period is about 5 to 14 days.

5. (Currently Amended) The method of claim 1, wherein the drug holiday period is about 14 days~~to 16 days~~.

6. (Previously Presented) The method of claim 1, wherein the drug administration period and the drug holiday period are each 14 days.

7. (Previously Presented) The method of claim 1, wherein a course consisting of an initial drug administration period of 14 days and a drug holiday period of 14 days is provided, followed by repetitions of the following combination of periods:

drug administration period: 5 days per week for 2 weeks; and

drug holiday period: 14 days.

8. (Previously Presented) The method of claim 1, wherein the daily dose contains about 15 to 240 mg of 3-methyl-1-phenyl-2-pyrazoline-5-one as an active ingredient, or about 15 to 240 mg of 3-methyl-1-phenyl-2-pyrazoline-5-one contained in a pharmaceutically acceptable salt of 3-methyl-1-phenyl-2-pyrazoline-5-one or a hydrate of 3-methyl-1-phenyl-2-pyrazoline-5-one or a pharmaceutically acceptable salt thereof as an active ingredient.

9. (Previously Presented) The method of claim 1, wherein the daily dose contains about 60 mg of 3-methyl-1-phenyl-2-pyrazoline-5-one as an active ingredient, or about 60 mg of 3-methyl-1-phenyl-2-pyrazoline-5-one contained in a pharmaceutically acceptable salt of 3-methyl-1-phenyl-2-pyrazoline-5-one or a hydrate of 3-methyl-1-phenyl-2-pyrazoline-5-one or a pharmaceutically acceptable salt thereof as an active ingredient.

10. (Previously Presented) The method of claim 1, wherein the administration is carried out once daily.

11. (Previously Presented) The method of claim 1, wherein the administration is a continuous administration.

12. (Previously Presented) The method of claim 11, wherein the continuous administration is intravenous infusion administration.

13. (Previously Presented) The method of claim 12, wherein the administration rate in the intravenous infusion administration is about 0.5 to 1 mg/minute with respect to 3-methyl-1-phenyl-2-pyrazoline-5-one as an active ingredient or 3-methyl-1-phenyl-2-pyrazoline-5-one contained in an active ingredient.

14. (Previously Presented) The method of claim 11, wherein the continuous administration is an administration form that is substantially equivalent to the intravenous infusion administration wherein the amount of 3-methyl-1-phenyl-2-pyrazoline-5-one as an active ingredient or 3-methyl-

1-phenyl-2-pyrazoline-5-one contained in an active ingredient administered per minute is about 0.5 to 1 mg.

15. (Previously Presented) The method of claim 1, wherein the symptoms caused by amyotrophic lateral sclerosis are decreased respiratory function, voice and speech disorders, dysphagia, or upper and lower extremity motor disorders.

16. (Previously Presented) The method of claim 1, wherein the treatment of amyotrophic lateral sclerosis or symptoms caused by amyotrophic lateral sclerosis and/or the suppression of the progression thereof is a suppression of decrease in respiratory function in amyotrophic lateral sclerosis.

17-32. (Cancelled)